Clinical Trials Logo

Epithelial Cancer Patients clinical trials

View clinical trials related to Epithelial Cancer Patients.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01320020 Terminated - Clinical trials for Epithelial Cancer Patients

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Start date: February 2011
Phase: Phase 1
Study type: Interventional

The study is designed as an open-label dose-escalation study to investigate the safety and tolerability of catumaxomab qwk in patients with epithelial cancer. The treatment period for dose escalation (dose limiting toxicity (DLT) period) consists of 4 weeks, comprising 4 single i.v. administrations of catumaxomab followed by 1 week for safety observations after each administration. All patients will be offered continuation of catumaxomab treatment at the same dose until disease progression or death, whichever occurs first.